Pharmacotherapy Rounds (PT Rounds) for Pharmacy Residents in Austin, Temple, Brownsville, Corpus Christi, and Magnolia 2024-25

Description: The University of Texas at Austin College of Pharmacy (UTCOP) Pharmacotherapy Rounds for Residents is a learning experience provided to residents participating in pharmacy residency programs affiliated with UTCOP. The program provides the opportunity for pharmacy residents to develop presentation skills in a safe, collegial space. The purpose of this experience is to disseminate up-to-date clinical information at the post-graduate level to resident and pharmacist colleagues.Pharmacotherapy Rounds will be held on some Wednesdays(12-1pm) and most Fridays (2-5pm) beginning in September and continue weekly as needed. Presentations will be presented either from room PHR 4.114or PHR 3.106 (depending on availability)at the College of Pharmacy or online using Zoom. Wednesday presentations will only be held on Zoom. Otherwise, it is presenter preference to present in person or online. All presentations will be broadcast using Zoom. All instructions, assignments, resources, rubrics and essential information will be on the Canvas website at https://canvas.utexas.edu/.

Date: Sep 1, 2024 03:00 AM - Jan 24, 2025 05:00 PM

Fee

$0.00

CE Hours

9.00

CE Units

0.900

Registration closes on Jan 31, 2025 12:00 AM

Activity Type

Knowledge

Fri, Sep 13, 2024

PPIs for EVeryone? Pantoprazole Use in Esophageal Varices - Domingo - Ascension PGY2 IM

Title: PPIs for EVeryone? Pantoprazole Use in Esophageal Varices

Faculty:

Ma. Emmanuelle (Ella) Domingo Vogt, PharmD
PGY2 Pharmacy Resident - Internal Medicine
Dell Seton Medical Center at the University of Texas

Disclosure: Dr. Domingo does not have any relevant financial relationship(s) with ineligible companies

Objectives:

Outline pathophysiology of cirrhosis and esophageal varices
Discuss guideline recommendations and literature on pantoprazole use in esophageal varices
Identify practice impact of pantoprazole use in esophageal varices

Gap Analysis:
Pantoprazole is commonly used in patients with an acute variceal bleed despite strong evidence for use. Some small studies have found that PPIs can reduce ulcer size post-EVL. On the other hand, pantoprazole has also shown to increase risk of hepatic encephalopathy and SBP especially with long term use. Questions remain if PPIs are indicated in decompensated cirrhosis patients, which patients benefit, and how long should we be using them.

Activity Number

0067-0000-24-087-L01-P/T

Date: 09/13/24

Time: 03:00 PM - 04:00 PM

CE Hours

1.00

Are Antistaphylococcal Penicillins Dead? A Review of Their Waning Efficacy in Deep-Seated Infections - Doan - Assension PGY2 ID

Title: Are Antistaphylococcal Penicillins Dead? A Review of Their Waning Efficacy in Deep-Seated Infections

Faculty:

Diana Doan, PharmD

PGY2 Pharmacy Resident - Infectious Diseases Dell Seton Medical Center at the University of Texas

Disclosure: Dr. Doan does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Identify preferred clinical indications of ASPs and develop a criteria of use
Analyze the impact and validity of the inoculum effect and blaZ gene
Compare and contrast the advantages of ASPs over cefazolin and their safety profile

Gap:

Despite evidence suggesting that cefazolin is better tolerated and comparably effective as antistaphylococcal penicillins (ASPs) for treating certain methicillin susceptible Staphylococcus aureus (MSSA) infections such as bacteremia. However, significant gaps remain in the current research for other deep seated infections. Notably, there is a lack of robust data on cefazolin’s efficacy against high-inoculum infections, such as infective endocarditis, spinal epidural abscesses, and CNS infections where ASPs might still have an advantage. This presentation will review literature, place of therapy of ASPs, and clinical implications of using cefazolin over ASPs.

Activity Number

0067-0000-24-088-L01-P/T

Date: 09/13/24

Time: 04:00 PM - 05:00 PM

CE Hours

1.00

Fri, Sep 20, 2024

Feeling The Pressure! A Review for Pharmacological Management of Pediatric Septic Shock Beyond Vasoactives - Hinojosa - Ascension PGY2 - Critical Care

Title: Feeling The Pressure! A Review for Pharmacological Management of Pediatric Septic Shock Beyond Vasoactives

Faculty:

Felipe Hinojosa, PharmD
PGY2 Critical Care Pharmacy Resident
Dell Children's Medical Center

Disclosure: Dr. Hinojosa does not have any relevant financial relationship(s) with ineligible companies

Objectives:

Review current pediatric surviving sepsis guidelines and treatment of septic shock in the PICU.
Analyze current literature on the use of corticosteroids in pediatric septic shock.
Examine current literature available on ancillary pharmacological treatment options for vasopressor refractory pediatric septic shock.
Develop recommendations for the pharmacological treatment of vasopressor refractory septic shock in pediatric patients.

Gap Analysis:

Pediatric sepsis is a leading cause of morbidity, mortality, and healthcare utilization for children worldwide. Current Pediatric Critical Care Medicine (PCCM) Surviving Sepsis guidelines do not have strong recommendations regarding pharmacological treatment with either hydrocortisone, methylene blue, vitamin C, or thiamine as adjunctive therapies for vasopressor refractory septic shock. Controversy exists on different dosing strategies and whether any of these therapies actually provide any clinical benefit. Additionally, there is very limited data on use of these therapies in both adult and pediatric patient populations. This presentation will examine a few studies comparing the efficacy and safety of different adjunctive pharmacologic therapies beyond vasopressors for the treatment of pediatric septic shock.

Activity Number

0067-0000-24-089-L01-P/T

Date: 09/20/24

Time: 03:00 PM - 04:00 PM

CE Hours

1.00

The CRASH Saga - An update on Tranexamic Acid in Trauma - Omisade - Ascension PGY1

Title: The CRASH Saga - An update on Tranexamic Acid in Trauma

Faculty:

Zaynab Omisade, PharmD

Pharmacy Resident PGY1

Dell Seton Medical Center at the University of Texas

Disclosure: Dr. Omisade does not have any relevant financial relationship(s) with ineligible companies

Objectives:

Discuss the pathophysiology of hypovolemic shock and trauma-induced coagulopathy (TIC)
Evaluate the role and evidence of tranexamic acid in the management of TIC.
Develop recommendations for the use of tranexamic acid in trauma patients.

Gap Analysis:

Since the publication of the CRASH-2 and MATTERs trials, new evidence has emerged regarding the use of tranexamic acid (TXA) in trauma patients. While CRASH-2 demonstrated a reduction in mortality with TXA use in bleeding trauma patients, subsequent studies like CRASH-3, STAAMP, and PATCH have provided additional insights into its efficacy and safety, particularly in specific trauma populations such as those with traumatic brain injury. However, these newer findings have not been widely integrated into clinical practice. This presentation will review recent data from these trials to determine how the latest evidence should inform the optimal use of TXA in trauma care

Activity Number

0067-0000-24-139-L01-P/T

Date: 09/20/24

Time: 04:00 PM - 05:00 PM

CE Hours

1.00

Fri, Sep 27, 2024

Eggs-tra Protection: Gonadotropin releasing hormone agonist (GnRHa) use for fertility preservation in pediatric patients receiving chemotherapy - Lowery - Ascension PGY1 Peds focus

Title: Eggs-tra Protection: Gonadotropin releasing hormone agonist (GnRHa) use for fertility preservation in pediatric patients receiving chemotherapy

Faculty:

Emily Lowery, PharmD

PGY1 Pharmacy Resident
Pharmacy - Dell Children's Medical Center

Disclosure: Dr. Lowery does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Explain why fertility preservation is needed for patients getting chemotherapy
Describe the mechanism of GnRH agonists in fertility preservation
Analyze current literature on the use of GnRH agonists for fertility preservation in pediatrics

Gap:

Nearly 15,000 children are diagnosed with cancer in the United States every year. Thankfully, due to advancements in treatment and supportive care, pediatric cancer survival rates have improved drastically over the last few decades. With improved survival rates it is important to think about the long term consequences of treatments used in pediatric cancer, such as infertility. Infertility is a potential side effect of many chemotherapy regimens used in pediatric cancer. Current options for fertility preservation in pediatric patients are limited, and can be expensive or invasive. Data supports the use of gonadotropin releasing hormone analogs (GnRHa) for fertility preservation in adult patients with breast cancer, but there is limited data in other types of cancer as well as in adolescent patients in general. This presentation will review the literature to clarify if GnRHa use is appropriate in the pediatric population.

Activity Number

0067-0000-24-142-L01-P/T

Date: 09/27/24

Time: 03:00 PM - 04:00 PM

CE Hours

1.00

Ironing Out the Details: Intravenous Iron Therapy In Heart Failure - Hamdan - Ascension PGY1

Title: Ironing Out the Details: Intravenous Iron Therapy In Heart Failure

Faculty:

Sally Hamdan, PharmD

PGY1 Pharmacy Resident

Dell Seton Medical Center at the University of Texas

Disclosure: Dr. Hamdan does not have any relevant financial relationship(s) with ineligible companies

Objectives:

Discuss the pathophysiology of iron deficiency in heart failure
Identify diagnostic criteria for iron deficiency in heart failure patient
Analyze available literature surrounding intravenous iron therapy in heart failure
Apply the findings to determine when iron therapy is appropriate in the management of chronic heart failure

Gap Analysis:

Iron deficiency (ID) is a common comorbidity in heart failure (HF) patients and is associated with worsened symptoms, decreased quality of life, and increased mortality. Despite the prevalence of ID in HF, the optimal management of this condition has been historically underemphasized. The traditional management of iron deficiency in heart failure has focused on oral iron supplementation or no specific treatment at all. This leaves a significant gap in the effective management of ID in HF patients. Despite updated guidelines recommending IV iron for specific HF patients, many healthcare providers are not fully aware of the significance of iron deficiency in HF, the limitations of oral iron therapy, and the benefits of IV iron as supported by recent clinical trials. There is a need for clear guidance on how to implement IV iron therapy in clinical practice, including patient selection and dosing regimens. This presentation will effectively educate healthcare professionals on the use of intravenous iron therapy in managing iron deficiency in heart failure patients, addressing existing knowledge gaps and promoting evidence-based practices.

Activity Number

0067-0000-24-140-L01-P/T

Date: 09/27/24

Time: 04:00 PM - 05:00 PM

CE Hours

1.00

Fri, Oct 04, 2024

Phenobarbit-All-In: Evaluating Phenobarbital Use in Alcohol Withdrawal - Fardoun - Ascension PharmAdmin PGY1

Title: Phenobarbit-All-In: Evaluating Phenobarbital Use in Alcohol Withdrawal

Faculty:

Hassan Fardoun, PharmD
PGY1 Pharmacy Resident
Dell Seton Medical Center at the University of Texas

Disclosure: Dr. Fardoun does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Describe the pathophysiology of alcohol withdrawal syndrome (AWS), clinical presentation, and complications
Identify current treatment modality for AWS, highlighting phenobarbital and benzodiazepines
Analyze clinical evidence supporting the use of phenobarbital for alcohol withdrawal management in the inpatient setting

Gap Analysis:

Phenobarbital has shown potential in the management of alcohol withdrawal syndrome (AWS), particularly as an adjunct or alternative to benzodiazepines. However, there remains a significant gap in the evidence supporting its use in the inpatient setting. This gap is especially worth investigating since most of the literature focuses on the intensive care (ICU) setting or emergency department (ED) where phenobarbital could serve as an alternative to traditional benzodiazepine therapies. Moreover, there is a lack of standardized protocols for its use in the inpatient setting, making it difficult for clinicians to confidently integrate phenobarbital into inpatient care where benzodiazepines may be ineffective or fail. This presentation will explore and evaluate the available literature on phenobarbital use as an alternative first-line agent, its efficacy and safety, and highlight key recommendations based on the studies available; hopefully, the suggested recommendations can be used in conjunction with guidelines and protocols for use by clinicians across the inpatient, ICU, or ED.

Activity Number

0067-0000-24-141-L01-P/T

Date: 10/04/24

Time: 03:00 PM - 04:00 PM

CE Hours

1.00

Fri, Oct 11, 2024

Discontinuation is a pain! Buprenorphine management for OUD in the perioperative setting - Garza - Ascension PGY1

Title: Discontinuation is a pain! Buprenorphine management for OUD in the perioperative setting

Faculty

Derek Garza, PharmD
PGY1 Pharmacy Resident
Dell Seton Medical Center at The University of Texas

Disclosure: Dr. Garza does not have any relevant financial relationship(s) with ineligible companies

Objectives

Discuss Current Opioid Use Disorder treatment recommendations
Interpret current literature on Buprenorphine in the perioperative setting for OUD patients
Develop recommendations for the treatment of OUD during the perioperative period

Gap Analysis

Opioid use disorder (OUD) is a public health crisis in America. Pharmacotherapy treatment of OUD is associated with improved outcomes and has been steadily increasing over recent years. Buprenorphine is one of the most common medications prescribed for OUD and has several pharmacologic advantages over methadone for OUD. However, many clinicians are concerned about its unique pharmacokinetic profile in the perioperative setting where acute pain is expected. Many clinicians lack the sufficient training to provide care for patients on buprenorphine for treatment of OUD The medications these patients are on are highly beneficial as they prevent a recurrence of use and provide harm reduction. It is important that pharmacists know the optimal treatment and recommendations for these patients to optimize outcomes regarding the OUD. This presentation will provide a literature review and evaluate whether buprenorphine should be continued during the perioperative period for patients who are on buprenorphine for OUD treatment.

Activity Number

0067-0000-24-143-L01-P/T

Date: 10/11/24

Time: 03:00 PM - 04:00 PM

CE Hours

1.00

Digesting the Risks: Perioperative Management of GLP-1 Agonists in CABG Surgery - Silvera - Ascension PGY1

Title: Digesting the Risks: Perioperative Management of GLP-1 Agonists in CABG Surgery

Faculty:

Kenina Silvera, PharmD

PGY1 Pharmacy Resident - Infectious Diseases Dell Seton Medical Center at the University of Texas

Disclosure: Dr. Silvera does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Describe concerns regarding perioperative management of GLP-1 agonists
Recall current recommendations on the perioperative management of GLP-1 agonists
Discuss current literature rationale for perioperative plans for GLP-1 agonists in CABG patients

Gap:

The topic being presented was submitted by a pharmacy specialist(s) in their area of expertise and has been deemed relevant & important to pharmacy practice. With increased use and popularity of GLP-1 receptor agonists (GLP-1 RAs) has come reports of increased gastric volumes despite appropriate fasting and risk of pulmonary aspiration under anesthesia. Based on their mechanism of action resulting in delayed gastric emptying, this risk is plausible. However, there is significant heterogeneity in guidance on perioperative management between different countries and organizations. This is particularly notable for patients undergoing elective coronary artery bypass grafting (CABG) procedures, many of whom have indications for GLP-1 RAs, such as obesity or type II diabetes mellitus. A review of the current evidence and literature is necessary to assess the risks and benefits of holding GLP-1 RAs pre-operatively and devise perioperative medication management plans and procedures.

Activity Number

0067-0000-24-144-L01-P/T

Date: 10/11/24

Time: 04:00 PM - 05:00 PM

CE Hours

1.00

Wed, Oct 23, 2024

Do - St. David's SAMC PGY1

Title: TBA

Faculty:

Tiffany Do, PharmD

PGY1 Pharmacy Resident

St Davids South Austin Hospital

Disclosure: Dr. Do does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 10/23/24

Time: 12:00 PM - 01:00 PM

Fri, Oct 25, 2024

Macklin - CommUnityCare PGY2

Title: TBA

Faculty:

Licamied Macklin, PharmD

PGY2 Pharmacy Resident CommUnityCare

Disclosure: Dr. Macklin does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 10/25/24

Time: 03:00 PM - 04:00 PM

Beck - CommUnityCare PGY2

Title: TBA

Faculty:

Sierra Beck, PharmD

PGY2 Pharmacy Resident CommUnityCare

Disclosure: Dr. Beck does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 10/25/24

Time: 04:00 PM - 05:00 PM

Wed, Nov 13, 2024

Valigura - Magnolia PGY1

Title: TBA

Faculty:

Kayla Valigura, PharmD

PGY1 Pharmacy Resident Magnolia

Disclosure: Dr. Valigura does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 11/13/24

Time: 12:00 PM - 01:00 PM

Fri, Nov 15, 2024

Hodge - St David's PGY1

Title: TBA

Faculty:

Alex Hodge, PharmD

PGY1 Pharmacy Resident St David's

Disclosure: Dr. Hodge does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 11/15/24

Time: 03:00 PM - 04:00 PM

Vu - St. David's PGY1

Title: TBA

Faculty:

Uyen Vu, PharmD

PGY1 Pharmacy Resident St David's

Disclosure: Dr. Vu does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 11/15/24

Time: 04:00 PM - 05:00 PM

Wed, Nov 20, 2024

Holthaus - CTVHCS PGY1

Title: TBA

Faculty:

Serra Holthaus, PharmD

PGY1 Pharmacy Resident CHRISTUS

Disclosure: Dr. Holthaus does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 11/20/24

Time: 12:00 PM - 01:00 PM

Fri, Nov 22, 2024

McKenzie - HEB PGY1

Title: TBA

Faculty:

Kendall McKenzie, PharmD

PGY1 Pharmacy Resident H.E.B.

Disclosure: Dr. McKenzie does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 11/22/24

Time: 03:00 PM - 04:00 PM

Carrillo - HEB PGY1

Title: TBA

Faculty:

Analisa Carrillo, PharmD

PGY1 Pharmacy Resident H.E.B.

Disclosure: Dr. Carrillo does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 11/22/24

Time: 04:00 PM - 05:00 PM

Fri, Dec 13, 2024

Lewis - Curative PGY1

Title: TBA

Faculty:

Alaina Lewis, PharmD

PGY1 Pharmacy Resident Curative

Disclosure: Dr. Lewis does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 12/13/24

Time: 03:00 PM - 04:00 PM

Wed, Dec 18, 2024

El-Sharif - Curative PGY1

Title: TBA

Faculty:

Mina El-Sharif, PharmD

PGY1 Pharmacy Resident Curative

Disclosure: Dr. El-Sharif does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 12/18/24

Time: 12:00 PM - 01:00 PM

Fri, Jan 10, 2025

Cyprian - Valley Baptist PGY1

Title: TBA

Faculty:

Sydney Cyprian, PharmD

PGY1 Pharmacy Resident Valley Baptist

Disclosure: Dr. Cyprian does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/10/25

Time: 03:00 PM - 04:00 PM

Campbell - Valley Baptist PGY1

Title: TBA

Faculty:

Joseph Campbell, PharmD

PGY1 Pharmacy Resident Valley Baptist

Disclosure: Dr. Campbell does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/10/25

Time: 03:00 PM - 04:00 PM

Wed, Jan 15, 2025

Hernandez - CTVHCS PGY1

Title: TBA

Faculty:

Pamela Hernandez, PharmD

PGY1 Pharmacy Resident

Disclosure: Dr. Hernandez does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/15/25

Time: 12:00 PM - 01:00 PM

Fri, Jan 17, 2025

Nghiem - CTVHCS PGY1

Title: TBA

Faculty:

Catherine Nghiem, PharmD

PGY1 Pharmacy Resident CTVHCS

Disclosure: Dr. Nghiem does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/17/25

Time: 03:00 PM - 04:00 PM

Boyle - CTVHCS PGY1

Title: TBA

Faculty:

Shannon Boyle, PharmD

PGY1 Pharmacy Resident CTVHCS

Disclosure: Dr. Boyle does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/17/25

Time: 04:00 PM - 05:00 PM

Wed, Jan 22, 2025

Nguyenly - CHRISTUS Sphon PGY1

Title: TBA

Faculty:

Angel Nguyenly, PharmD

PGY1 Pharmacy Resident CHRISTUS

Disclosure: Dr. Nguyenly does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/22/25

Time: 12:00 PM - 01:00 PM

Fri, Jan 24, 2025

Gill - CHRISTUS Spohn PGY1

Title: TBA

Faculty:

Mariana Gill, PharmD

PGY1 Pharmacy Resident CHRISTUS

Disclosure: Dr. Gill does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/24/25

Time: 02:00 PM - 03:00 PM

Serventi - CHRISTUS Spohn PGY1

Title: TBA

Faculty:

Radha Serventi, PharmD

PGY1 Pharmacy Resident CHRISTUS

Disclosure: Dr. Serventi does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/24/25

Time: 03:00 PM - 04:00 PM

Diaz - CHRISTUS Spohn PGY1

Title: TBA

Faculty:

Gabrielle Diaz, PharmD

PGY1 Pharmacy Resident CHRISTUS

Disclosure: Dr. Diaz does not have any relevant financial relationship(s) with ineligible companies

Learning Objectives:

Gap:

TBA

Date: 01/24/25

Time: 04:00 PM - 05:00 PM